News & Events

• May 23, 2013
  

  Leading US and European Medical Public-Private Partnerships Announce Agreement

  The Predictive Safety Testing Consortium (PSTC) led by the Critical Path Institute (C-Path) and the Safer and Faster Evidence-based Translation (SAFE-T) consortium sponsored by the Innovative Medicines Initiative (IMI), announced today the signature of an agreement to work together in their efforts to improve drug safety.
• June 10, 2010
  

  Critical Path Institute’s Predictive Safety Testing Consortium Announces First-Ever Qualification Decision by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).

  For the first time, new biomarker tests to detect drug-induced kidney injury have been accepted by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
• May 10, 2010
  

  Critical Path Institute’s Predictive Safety Testing Consortium Announces Special Issue of Nature Biotechnology Dedicated to Newly Qualified Kidney Safety Biomarkers

  A special May 10, 2010 issue of Nature Biotechnology (NBT) includes ten scientific publications from Critical Path Institute’s Predictive Safety Testing Consortium’s evaluation of seven kidney biomarkers for use in drug safety assessment.
• January 22, 2009
  

  Japanese PMDA Announces First Biomarker Qualification

  The unprecedented sharing of data by the industry has facilitated regulatory agencies to receive, review and approve new methods as qualified for use in drug development. The use of these new tests can now be used in laboratory research to predict the safety of experimental drugs, allowing drugs to reach the market faster and with...
• March 10, 2007
  

  C-Path Adopts Rosetta Resolver® System for the PSTC

  Rosetta Biosoftware announced today that The Critical Path Institute (C-Path) adopted the Rosetta Resolver® system for C-Path’s Predictive Safety Testing Consortium.